{"gene":"GALNT2","run_date":"2026-06-10T01:55:20","timeline":{"discoveries":[{"year":2011,"finding":"ppGalNAc-T2 (GALNT2) directly O-glycosylates apolipoprotein C-III (apoC-III); a loss-of-function mutation impairs this glycosylation, leading to attenuated apoC-III inhibition of lipoprotein lipase (LPL) and improved postprandial triglyceride clearance. An apoC-III-based peptide was validated as a substrate for ppGalNAc-T2, and neuraminidase removal of sialic acids from apoC-III glycans decreased its ability to inhibit LPL.","method":"In vitro glycosylation assay with apoC-III-based peptide substrate; neuraminidase treatment; plasma glycoproteomics in human carriers of GALNT2 loss-of-function mutation","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro substrate assay with mutagenesis-equivalent (loss-of-function mutant), peptide glycosylation assay, and functional neuraminidase experiment confirming mechanistic link to LPL inhibition; replicated in human subjects","pmids":["22152306"],"is_preprint":false},{"year":2016,"finding":"GALNT2 deficiency reduces plasma PLTP (phospholipid transfer protein) activity and lowers HDL-C across mammals. O-glycoproteomics of a GALNT2-deficient human validated ANGPTL3 and ApoC-III as direct GalNAc-T2 substrates; additional rodent glycoproteomics identified PLTP as a substrate. Hepatic reconstitution of Galnt2 in mice rescued plasma PLTP activity.","method":"O-glycoproteomics in human GALNT2-deficient subject and rodents; hepatic Galnt2 reconstitution in mice; plasma PLTP activity assay","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vivo glycoproteomics, rescue by hepatic reconstitution, replicated across multiple mammalian species and orthogonal assays","pmids":["27508872"],"is_preprint":false},{"year":2011,"finding":"GALNT2 modifies O-glycans on EGFR in hepatocellular carcinoma (HCC) cells, altering EGFR responses after EGF binding and suppressing EGF-induced cell growth, migration, and invasion. Inhibiting EGFR with erlotinib rescued the pro-malignant phenotypes caused by GALNT2 knockdown, establishing EGFR as a key downstream mediator.","method":"siRNA knockdown and overexpression of GALNT2 in HCC cells; in vitro growth/migration/invasion assays; in vivo xenograft; erlotinib epistasis experiment; Western blot for EGFR signaling","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (EGFR inhibitor rescue), loss- and gain-of-function, in vitro and in vivo, replicated in multiple cancer contexts","pmids":["21990321"],"is_preprint":false},{"year":2013,"finding":"GALNT2 downregulation increases ENPP1 expression and impairs insulin receptor (IR), IRS-1, and Akt phosphorylation, as well as insulin-mediated suppression of PEPCK in human HepG2 liver cells. Conversely, GALNT2 overexpression reduces ENPP1 levels and enhances insulin signaling. GALNT2 was identified as a trans-acting factor binding the ENPP1 3′-UTR by RNA pull-down and mass spectrometry.","method":"RNA pull-down with mass spectrometry; RT-PCR; Western blot for ENPP1, IR, IRS-1, Akt phosphorylation; ELISA for IR autophosphorylation; siRNA knockdown and overexpression in HepG2 cells","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA pull-down/MS plus functional insulin signaling readouts in a single lab, multiple orthogonal methods","pmids":["23500900"],"is_preprint":false},{"year":2014,"finding":"GALNT2 modifies O-glycans on EGFR in oral squamous cell carcinoma (OSCC) cells, enhancing EGF-induced EGFR and AKT phosphorylation and promoting cell migration and invasion. VVA lectin pull-down confirmed increased Tn antigen on EGFR upon GALNT2 overexpression.","method":"Overexpression and siRNA knockdown of GALNT2 in SAS cells; Vicia villosa agglutinin (VVA) pull-down assay; transwell migration/invasion assay; Western blot","journal":"Oral oncology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — lectin pull-down and functional assays, single lab, consistent with parallel HCC findings","pmids":["24582885"],"is_preprint":false},{"year":2016,"finding":"GALNT2 suppresses malignant phenotypes in gastric adenocarcinoma (GCA) by modifying O-glycosylation of MET (hepatocyte growth factor receptor), reducing its phosphorylation. GALNT2 knockdown decreased Tn antigen expression on MET and enhanced MET phosphorylation; MET inhibitor PHA665752 reversed the pro-malignant effects of GALNT2 knockdown.","method":"siRNA knockdown of GALNT2 in GCA cells; Tn antigen detection by Western blot; in vitro growth/migration/invasion; in vivo metastasis; MET inhibitor epistasis","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with MET inhibitor, loss-of-function with in vivo validation, single lab","pmids":["26848976"],"is_preprint":false},{"year":2018,"finding":"GALNT2 suppresses GCA malignancy through O-glycosylation of EGFR, reducing EGFR and Akt phosphorylation. GALNT2 knockdown decreased Tn antigen on EGFR; EGFR inhibitor gefitinib and Akt inhibitor MK2206 reversed pro-invasive effects of GALNT2 knockdown.","method":"siRNA knockdown in AGS/MKN28 cells; Western blot for pEGFR, pAkt, Tn antigen; migration/invasion assays; gefitinib/MK2206 epistasis","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis with EGFR/Akt inhibitors, Tn antigen detection, single lab","pmids":["30323967"],"is_preprint":false},{"year":2018,"finding":"A GalNAc-T2 F104S mutant (not located at the active site) loses peptide substrate binding. Crystal structure of the mutant bound to UDP-GalNAc, combined with STD-NMR and MD simulations, revealed that the flexible loop is disordered in the mutant. 19F NMR demonstrated that wild-type GalNAc-T2 reaches the active state only in the presence of UDP-GalNAc, establishing a UDP-GalNAc-dependent induced-fit catalytic mechanism.","method":"Crystal structure of F104S mutant bound to UDP-GalNAc; saturation transfer difference (STD) NMR; 19F NMR spectroscopy; molecular dynamics simulations; active-site mutagenesis (F104S)","journal":"Chemistry (Weinheim an der Bergstrasse, Germany)","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with NMR validation and MD simulations, multiple orthogonal methods establishing the induced-fit mechanism","pmids":["29601100"],"is_preprint":false},{"year":2019,"finding":"GalNAc-T2 glycosylates IgA1 hinge-region in a semi-ordered process: the catalytic domain selects four initial sites based on amino-acid sequence recognition, and both the catalytic and lectin domains participate in subsequent site selections. The lectin domain enhances glycan density by increasing pathway exploration, linking site-specific glycan addition to overall clustered glycan density.","method":"In vitro glycosylation assay with IgA1 hinge-region peptide; LC-MS analysis of glycoforms; domain mutant analysis (catalytic vs. lectin domain)","journal":"Glycobiology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro assay with LC-MS, domain-specific functional dissection, single lab but multiple orthogonal approaches","pmids":["30759204"],"is_preprint":false},{"year":2019,"finding":"GALNT2 facilitates glioma malignancy by O-glycosylating EGFR (detected by Tn antigen on EGFR via lectin pull-down), increasing EGFR phosphorylation and activating the PI3K/Akt/mTOR pathway, and regulating downstream effectors (p21, CDK4, cyclinD1, MMP2, MMP9).","method":"GALNT2 knockdown and overexpression in glioma cell lines; lectin pull-down; Western blot for pEGFR, PI3K/Akt/mTOR components; in vivo orthotopic xenograft with GALNT2 shRNA","journal":"Clinical science (London, England : 1979)","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — lectin pull-down for substrate, functional in vitro and in vivo experiments, single lab","pmids":["31076460"],"is_preprint":false},{"year":2012,"finding":"GALNT2 O-glycosylates β1-integrin (increasing Tn antigen on β1-integrin detected by VVA binding) in extravillous trophoblast (EVT) cells, enhancing cell-collagen IV adhesion but suppressing FAK phosphorylation, cell migration, and invasion.","method":"Overexpression of GALNT2 in HTR8/SVneo cells; VVA lectin binding assay for Tn antigen on β1-integrin; collagen IV adhesion assay; transwell migration/invasion; Western blot for phospho-FAK","journal":"Placenta","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — lectin pull-down confirming substrate glycosylation, FAK signaling readout, single lab with multiple assays","pmids":["23117232"],"is_preprint":false},{"year":2020,"finding":"GALNT2-mediated O-glycosylation near the ANGPTL3 cleavage site inhibits proprotein convertase (PC)-mediated cleavage of ANGPTL3. In primary hepatocytes and in vivo in mice, suppression of Galnt2 dramatically increases Angptl3 cleavage, while Galnt2 overexpression blocks cleavage; cleavage is also blocked by PC inhibition.","method":"Galnt2 overexpression and siRNA knockdown in primary hepatocytes and in vivo mouse liver; Western blot for ANGPTL3 cleavage products; PC inhibitor comparison","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro and in vivo experiments with both gain- and loss-of-function, PC inhibitor epistasis confirming mechanism, multiple orthogonal approaches","pmids":["32999434"],"is_preprint":false},{"year":2020,"finding":"GALNT2 loss of function causes a congenital disorder of glycosylation (GALNT2-CDG) characterized by loss of O-glycosylation of ApoC-III (a non-redundant GALNT2 substrate), low HDL-C, and multisystem developmental abnormalities. Rodent models of GALNT2-CDG recapitulate neurodevelopmental phenotypes including cerebellar motor deficits, decreased sociability, and impaired sensory processing.","method":"Human patient biochemical and glycoproteomics analysis; mouse and rat GALNT2 knockout models; behavioral phenotyping","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — validated in human patients plus two rodent model systems with ApoC-III glycoproteomics and behavioral readouts","pmids":["32293671"],"is_preprint":false},{"year":2019,"finding":"GALNT2 promotes adipogenesis and enhances insulin-induced IR, IRS1, and AKT activation in mouse 3T3-L1 preadipocytes, with the insulin-sensitizing effect abolished during late adipocyte maturation. GALNT2's effect is paralleled by coordinated changes in Enpp1 expression.","method":"Stable GALNT2 overexpression in 3T3-L1 cells; Oil Red-O staining; fluorimetric triglyceride assay; confocal microscopy of lipid droplets; Western blot for IR, IRS1, JNK, AKT phosphorylation; RT-PCR for adipogenesis genes","journal":"International journal of obesity (2005)","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — multiple cellular readouts with overexpression, single lab","pmids":["31040393"],"is_preprint":false},{"year":2022,"finding":"GALNT2 modifies O-glycans on ITGA5 (integrin alpha 5) in non-small cell lung cancer cells, affecting activation of the PI3K/Akt and MAPK/ERK pathways. miR-30d was identified as a negative regulator of GALNT2 by high-throughput sequencing.","method":"Lectin pull-down for O-glycosylation of ITGA5; gain- and loss-of-function experiments; Western blot for PI3K/Akt, MAPK/ERK; in vivo tumor formation; miRNA high-throughput sequencing","journal":"Cellular & molecular biology letters","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — lectin pull-down confirming ITGA5 as substrate, signaling pathway readouts, single lab","pmids":["36058918"],"is_preprint":false},{"year":2022,"finding":"GALNT2 modifies O-glycans on AXL receptor tyrosine kinase in colorectal cancer cells and regulates AXL protein levels via the proteasome-dependent pathway; GALNT2-promoted invasiveness was significantly reversed by AXL siRNA knockdown.","method":"GALNT2 overexpression and CRISPR/Cas9 knockout; siRNA knockdown; lectin pull-down for O-glycans on AXL; proteasome inhibitor experiments; migration/invasion and peritoneal metastasis assays","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO plus lectin pull-down for substrate identification, epistasis with AXL siRNA, single lab","pmids":["36409270"],"is_preprint":false},{"year":2022,"finding":"The insulin receptor is a novel O-glycosylation substrate of GalNAc-T2. Galnt2-knockout mice display decreased adiposity, altered insulin signaling, and a shift in energy substrate utilization in the inactive phase.","method":"Galnt2-/- mouse model; glycoproteomics identifying insulin receptor as substrate; metabolic phenotyping including indirect calorimetry; GWAS correlation in UK Biobank","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo glycoproteomics identifying insulin receptor as substrate, KO mouse metabolic phenotyping, single lab","pmids":["35304331"],"is_preprint":false},{"year":2021,"finding":"Computational flexible docking of peptide substrates into GalNAc-T2 identified enzyme residues R362, K363, Q364, H365, and W331 as regulators of pocket size and peptide binding at the -1 position, and K281 and K363 as gating residues at the +1 position, explaining the finely tuned peptide substrate specificity of GalNAc-T2.","method":"Rosetta Monte Carlo-minimization flexible docking of 361 peptides with experimental glycosylation efficiency data; computational scanning of enzyme-peptide interactions","journal":"ACS catalysis","confidence":"Low","confidence_rationale":"Tier 4 / Moderate — computational prediction validated against experimental dataset but no direct mutagenesis of identified residues performed in this study","pmids":["34322281"],"is_preprint":false},{"year":2023,"finding":"In vivo O-glycoproteomics in Galnt2-null mice identified a network of glycoproteins lacking GalNAc-T2-specific O-glycans across nine mouse tissues, establishing tissue-specific regulation of O-glycosites. Known functions of these glycoproteins are consistent with the complex metabolic phenotypes of Galnt2-null animals.","method":"Quantitative glycoproteomics and proteomics across nine mouse tissues using HCD-triggered ETD/HCD MS; Galnt2-null mouse model comparison","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — comprehensive in vivo MS glycoproteomics in KO vs. WT across multiple tissues with rigorous quantitative workflow","pmids":["37862385"],"is_preprint":false},{"year":2023,"finding":"GALNT2 modifies O-glycans on IGF1R in non-small cell lung cancer cells (detected by lectin pull-down), and IGF1R affects expression of apoptosis-related genes. GALNT2 knockdown-mediated radiosensitization was enhanced by IGF1R inhibition. miR-30a-5p was validated as an upstream negative regulator of GALNT2 by luciferase reporter assay.","method":"Lectin pull-down for O-glycans on IGF1R; GALNT2 knockdown; in vitro and in vivo radiosensitivity assays; IGF1R inhibitor epistasis; miRNA array; dual luciferase reporter assay","journal":"Cell biology and toxicology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — lectin pull-down for substrate, epistasis with IGF1R inhibitor, luciferase validation of upstream regulator, single lab","pmids":["37597090"],"is_preprint":false},{"year":2024,"finding":"GALNT2 overexpression specifically in the pancreas (conditional transgenic mouse) causes loss of acinar mass and pancreatic steatosis (heterozygous) or complete pancreatic loss with lethal phenotype (homozygous). Adipocytes in the pancreas were shown to originate via transdifferentiation from pancreatic cells (reporter gene mouse). Additional O-glycosylation sites introduced by GalNT2 overexpression were identified by PNA lectin enrichment and mass spectrometric proteome analysis.","method":"Conditional transgenic mouse with pancreas-specific GalNT2 overexpression; reporter gene mouse for lineage tracing; PNA lectin enrichment and mass spectrometry","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo conditional overexpression with histological and proteomic validation, single lab","pmids":["39613794"],"is_preprint":false},{"year":2024,"finding":"GALNT2 knockdown in renal cell carcinoma cells increased p-LATS2/LATS2 expression and subsequent YAP phosphorylation/degradation, suppressing cell proliferation. This was rescued by LATS2 knockdown, placing GALNT2 upstream of LATS2 in this pathway. miR-139-5p was validated as a direct negative regulator of GALNT2 via dual luciferase reporter assay targeting the GALNT2 3′-UTR.","method":"shRNA knockdown of GALNT2; LATS2 epistasis (double knockdown rescue); Western blot for p-LATS2, LATS2, p-YAP, YAP; dual luciferase reporter assay for miR-139-5p/GALNT2 3′-UTR interaction","journal":"Discover oncology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — epistasis rescue experiment plus luciferase validation of upstream regulator, single lab","pmids":["38478152"],"is_preprint":false},{"year":2025,"finding":"GALNT2 is an interferon-stimulated gene (ISG) that restricts replication of multiple coronaviruses and influenza A viruses in vitro and in vivo. Mechanistically, GALNT2-dependent O-linked glycosylation of the SARS-CoV-2 spike protein at serine 810/813 regulates viral glycoprotein proteolytic processing and impairs virus-cell fusion. Human GALNT2 loss-of-function variants are associated with elevated risk of COVID-19 hospitalization.","method":"Transcriptomic profiling of IFNAR-/- vs. wild-type mouse lungs; single-cell RNA-seq of COVID-19 patient samples; in vitro viral replication assays; in vivo infection models; site-directed mutagenesis of spike S810/813; mechanistic fusion assay","journal":"Nature microbiology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro and in vivo antiviral experiments, mutagenesis of glycosylation sites on viral substrate, multiple virus types tested, human genetic validation","pmids":["41387548"],"is_preprint":false},{"year":2025,"finding":"Galnt2-expressing neurons in the ventromedial hypothalamus (VMH) form a VMH→PVH→LPGi→liver neurocircuit that detects neuroglycopenia and drives hepatic glucose production via intrahepatic sympathetic activation. Galnt2 functions as both a genetic marker and molecular brake of VMH glucose-inhibited neurons, modulating the glycemic threshold for hypoglycemia perception.","method":"Viral tracing; single-nucleus RNA sequencing; behavioral and metabolic phenotyping; optogenetic/chemogenetic circuit dissection","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — circuit tracing and snRNA-seq with functional circuit manipulation, single study; Galnt2 used as a neuronal marker/target rather than enzymatic substrate identified","pmids":["41092902"],"is_preprint":false},{"year":2024,"finding":"Neuronal-specific conditional knockout of Galnt2 in mice causes behavioral deficits (locomotion, motor coordination, sociability, learning, memory) and spontaneous seizures, recapitulating GALNT2-CDG neurology. Glycoproteomics of cortical synaptosomes identified a non-redundant, isoform-specific Galnt2 contribution to the synaptosomal O-glycoproteome, identifying disrupted O-glycosites on candidate neuronal glycoproteins.","method":"Pan-neuronal conditional Galnt2 knockout mouse; behavioral battery (locomotion, rotarod, social interaction, Morris water maze, EEG for seizures); cortical synaptosomal glycoproteomics","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with glycoproteomics and behavioral phenotyping; preprint, not peer-reviewed","pmids":["bio_10.1101_2024.09.30.615951"],"is_preprint":true},{"year":2011,"finding":"Recombinant soluble GalNAc-T2 produced in insect (Sf9) cells was enzymatically active, catalyzing GalNAc transfer to synthetic IgA1 hinge-region peptide using UDP-GalNAc as donor. This confirmed the enzyme's activity toward IgA1 hinge-region peptide substrates.","method":"Baculovirus expression and purification of recombinant GalNAc-T2; in vitro enzymatic activity assay quantifying GalNAc attachment to synthetic IgA1 HR peptide; mass spectrometric confirmation of protein identity","journal":"Protein expression and purification","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro enzymatic reconstitution demonstrating activity toward IgA1 HR substrate, single study with single method","pmids":["22033505"],"is_preprint":false},{"year":2023,"finding":"GALNT2 promotes CD44 expression to sustain glioblastoma stem cells (GSCs), and STAT3 directly activates GALNT2 transcription by binding to the GALNT2 promoter. A GALNT2 inhibitor suppressed GSC self-maintenance in vitro and in vivo.","method":"GALNT2 knockdown in GSCs; CD44 expression analysis; ChIP assay for STAT3 binding to GALNT2 promoter; pharmacological GALNT2 inhibitor; in vivo xenograft","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP assay for upstream transcriptional regulation, loss-of-function with downstream substrate (CD44) analysis, single lab","pmids":["37000153"],"is_preprint":false},{"year":2024,"finding":"GALNT2 was identified as a regulator of human commissural axon guidance by floor plate; CRISPR knockout of GALNT2 in human floor plate organoids impaired floor plate-mediated guidance of commissural axons in midline assembloids, implicating O-linked glycosylation in human-specific axon guidance.","method":"CRISPR knockout screen in human floor plate organoids (hFpO) assembled with spinal cord organoids (hSpO); secretome profiling; axon guidance assay in midline assembloids","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single arrayed CRISPR screen phenotype in an organoid model, preprint, mechanistic substrate not identified","pmids":["bio_10.1101_2024.06.26.600229"],"is_preprint":true},{"year":2024,"finding":"Isoferulic acid (IFA) directly interacts with GALNT2 protein (shown by Co-IP, molecular docking, and fluorescence spectroscopy) and inhibits alcohol-induced downregulation of GALNT2 activity in gastric epithelial cells, thereby promoting mucin synthesis.","method":"Co-immunoprecipitation; molecular docking; fluorescence spectroscopy; GALNT2 activity assay; in vivo rat gastric injury model; H&E staining; gastric hexosamine content","journal":"Nutrients","confidence":"Low","confidence_rationale":"Tier 3 / Weak — Co-IP and docking for interaction, functional assay, but mechanism is indirect and single lab with limited rigor","pmids":["38999895"],"is_preprint":false}],"current_model":"GALNT2 encodes a Golgi-localized polypeptide N-acetylgalactosaminyltransferase (GalNAc-T2) that catalyzes the first committed step of mucin-type O-glycosylation via a UDP-GalNAc-dependent induced-fit mechanism; it O-glycosylates a broad array of protein substrates—including EGFR, MET, AXL, IGF1R, ITGA5, β1-integrin, the insulin receptor, ApoC-III, ANGPTL3, and PLTP—thereby regulating receptor tyrosine kinase signaling, lipoprotein metabolism (HDL-C and triglycerides through ANGPTL3 cleavage and LPL activity), insulin signaling via ENPP1 suppression, adipogenesis, antiviral defense through viral glycoprotein processing, and neuronal function, with loss-of-function causing a multi-system congenital disorder of glycosylation (GALNT2-CDG)."},"narrative":{"mechanistic_narrative":"GALNT2 encodes a Golgi polypeptide N-acetylgalactosaminyltransferase (GalNAc-T2) that initiates mucin-type O-glycosylation by transferring GalNAc from UDP-GalNAc onto serine/threonine residues of secreted and membrane substrates [PMID:22152306, PMID:22033505]. Catalysis proceeds through a UDP-GalNAc-dependent induced-fit mechanism in which donor binding orders a flexible loop and drives the enzyme into its active state; a non-active-site F104S mutation abolishes peptide substrate binding by leaving this loop disordered [PMID:29601100]. The catalytic domain selects initial glycosylation sites by sequence recognition while the lectin domain expands site exploration to increase clustered glycan density, as shown for the IgA1 hinge region [PMID:30759204]. In hepatic and metabolic physiology, GalNAc-T2 O-glycosylates ApoC-III, ANGPTL3 and PLTP: glycosylation modulates ApoC-III-mediated inhibition of lipoprotein lipase, blocks proprotein-convertase cleavage of ANGPTL3, and sustains plasma PLTP activity, thereby controlling triglyceride clearance and HDL-C [PMID:22152306, PMID:27508872, PMID:32999434]. GalNAc-T2 also glycosylates the insulin receptor and influences insulin signaling, in part through coordinated suppression of ENPP1, and promotes adipogenesis [PMID:23500900, PMID:35304331, PMID:31040393]. Across multiple cancers it O-glycosylates receptor tyrosine kinases and adhesion receptors—EGFR, MET, AXL, IGF1R, ITGA5 and β1-integrin—tuning downstream PI3K/Akt, MAPK/ERK and FAK signaling with context-dependent suppressive or promoting effects on growth, migration and invasion [PMID:21990321, PMID:26848976, PMID:36058918, PMID:36409270, PMID:23117232]. As an interferon-stimulated gene, GALNT2 O-glycosylates the SARS-CoV-2 spike at S810/813 to restrict viral glycoprotein processing and cell fusion, conferring antiviral activity [PMID:41387548]. Loss of function causes a multisystem congenital disorder of glycosylation (GALNT2-CDG) with loss of ApoC-III O-glycosylation, low HDL-C, and neurodevelopmental phenotypes recapitulated in rodent models [PMID:32293671].","teleology":[{"year":2011,"claim":"Established that GalNAc-T2 directly O-glycosylates a physiological substrate (ApoC-III) and that this modification is functionally consequential for lipid metabolism, linking the enzyme to triglyceride handling.","evidence":"In vitro peptide glycosylation, neuraminidase treatment, and plasma glycoproteomics in human loss-of-function carriers; recombinant enzyme activity on IgA1 hinge peptide","pmids":["22152306","22033505"],"confidence":"High","gaps":["Did not resolve which other plasma glycoproteins drive the metabolic phenotype","Quantitative contribution of ApoC-III glycosylation to systemic triglyceride levels not isolated"]},{"year":2011,"claim":"Showed GalNAc-T2 glycosylation is not confined to secreted proteins but also modifies a membrane receptor (EGFR), establishing a route by which O-glycosylation tunes receptor tyrosine kinase signaling and tumor behavior.","evidence":"siRNA/overexpression in HCC cells, xenograft, and erlotinib epistasis with EGFR signaling readouts","pmids":["21990321"],"confidence":"High","gaps":["Specific EGFR O-glycosites not mapped","Direct vs. indirect modification of EGFR not distinguished in this study"]},{"year":2012,"claim":"Extended the receptor-substrate model to adhesion machinery by showing β1-integrin O-glycosylation alters cell-matrix adhesion and FAK signaling, indicating GalNAc-T2 controls cell migration through integrin glycosylation.","evidence":"GALNT2 overexpression in trophoblast cells with VVA lectin pull-down, adhesion and migration assays, phospho-FAK Western blot","pmids":["23117232"],"confidence":"Medium","gaps":["Lectin detection does not pinpoint the modified β1-integrin residues","Single overexpression system"]},{"year":2013,"claim":"Uncovered a glycosylation-independent branch in which GalNAc-T2 acts as a trans-acting factor on the ENPP1 3'-UTR to regulate insulin receptor signaling, broadening its role beyond enzymatic O-glycosylation.","evidence":"RNA pull-down/MS, knockdown/overexpression in HepG2 cells, insulin signaling and PEPCK readouts","pmids":["23500900"],"confidence":"Medium","gaps":["Mechanism of ENPP1 3'-UTR binding by a Golgi glycosyltransferase not reconciled with its catalytic function","Single-lab RNA pull-down without reciprocal validation"]},{"year":2016,"claim":"Confirmed ANGPTL3 and PLTP as direct in vivo substrates and demonstrated rescue by hepatic reconstitution, cementing GalNAc-T2's causal role in HDL-C and lipid transfer physiology across mammals.","evidence":"O-glycoproteomics in human-deficient subject and rodents, hepatic Galnt2 reconstitution in mice, PLTP activity assay","pmids":["27508872"],"confidence":"High","gaps":["Relative metabolic weight of PLTP vs. ANGPTL3 vs. ApoC-III not partitioned"]},{"year":2018,"claim":"Defined the catalytic logic of the enzyme by showing donor (UDP-GalNAc) binding orders a flexible loop to reach the active state, explaining how substrate recognition is gated by an induced-fit mechanism.","evidence":"Crystal structure of F104S mutant with UDP-GalNAc, STD-NMR, 19F NMR, MD simulations, active-site mutagenesis","pmids":["29601100"],"confidence":"High","gaps":["Does not address how the lectin domain integrates with the catalytic cycle","Single-substrate structural context"]},{"year":2019,"claim":"Resolved how site-specific and clustered O-glycan density arise, attributing initial site selection to the catalytic domain and density amplification to lectin-domain-driven pathway exploration.","evidence":"In vitro IgA1 hinge glycosylation with LC-MS glycoform analysis and catalytic vs. lectin domain mutants","pmids":["30759204"],"confidence":"High","gaps":["Whether the same domain division governs membrane-receptor substrates is untested"]},{"year":2019,"claim":"Showed receptor-substrate effects are context-dependent, with EGFR/MET glycosylation promoting malignancy in some tumors and suppressing it in others, indicating tissue-specific signaling outcomes of the same modification.","evidence":"Lectin pull-down and inhibitor epistasis across glioma, gastric, oral cancer models with PI3K/Akt/mTOR and FAK readouts; insulin-sensitizing adipogenesis in 3T3-L1","pmids":["31076460","24582885","26848976","30323967","31040393"],"confidence":"Medium","gaps":["Molecular basis for opposite directionality across tissues unexplained","Glycosites on each receptor not mapped"]},{"year":2020,"claim":"Provided in vivo mechanism for the lipid phenotype by showing O-glycosylation near the ANGPTL3 cleavage site blocks proprotein-convertase processing, directly coupling GalNAc-T2 to ANGPTL3 activation.","evidence":"Galnt2 gain/loss in primary hepatocytes and mouse liver, ANGPTL3 cleavage Western blots, PC inhibitor epistasis","pmids":["32999434"],"confidence":"High","gaps":["Stoichiometry of glycan occupancy needed to block cleavage not quantified"]},{"year":2020,"claim":"Established GALNT2 loss as the cause of a defined human congenital disorder of glycosylation with multisystem and neurodevelopmental phenotypes, validated in rodent models.","evidence":"Human patient biochemistry/glycoproteomics, mouse and rat knockouts with behavioral phenotyping","pmids":["32293671"],"confidence":"High","gaps":["Which substrate losses drive the neurological phenotype not pinned down"]},{"year":2022,"claim":"Expanded the substrate repertoire to additional receptors (AXL, ITGA5, insulin receptor, IGF1R) and connected glycosylation to receptor stability, downstream pathway activation, and metabolic energy utilization.","evidence":"Lectin pull-down, CRISPR KO, proteasome inhibition, glycoproteomics in Galnt2-/- mice, metabolic phenotyping, inhibitor epistasis","pmids":["36409270","36058918","35304331","37597090"],"confidence":"Medium","gaps":["Direct glycosite assignments on these receptors largely absent","Single-lab findings per receptor"]},{"year":2023,"claim":"Generated a comprehensive in vivo, tissue-specific map of GalNAc-T2-dependent O-glycosites, providing the substrate network underlying the enzyme's pleiotropic phenotypes.","evidence":"Quantitative glycoproteomics across nine tissues in Galnt2-null vs. WT mice; STAT3 ChIP for transcriptional control of GALNT2 in glioblastoma stem cells","pmids":["37862385","37000153"],"confidence":"High","gaps":["Functional consequences of most individual glycosites untested","Tissue-specific regulators of GALNT2 expression incompletely defined"]},{"year":2025,"claim":"Defined an antiviral function for GALNT2 as an interferon-stimulated gene that glycosylates viral spike protein to impair proteolytic priming and fusion, with human genetic support linking loss of function to COVID-19 severity.","evidence":"IFNAR-/- transcriptomics, scRNA-seq of patients, in vitro/in vivo infection, spike S810/813 mutagenesis, fusion assays, human variant association","pmids":["41387548"],"confidence":"High","gaps":["Breadth of viral glycoprotein substrates beyond coronaviruses/influenza not fully delineated"]},{"year":2025,"claim":"Implicated Galnt2 in central glucose sensing, marking and braking VMH glucose-inhibited neurons within a hypothalamus-to-liver circuit controlling hepatic glucose production.","evidence":"Viral tracing, snRNA-seq, optogenetic/chemogenetic circuit dissection, metabolic phenotyping","pmids":["41092902"],"confidence":"Medium","gaps":["Whether the neuronal role depends on enzymatic O-glycosylation or marker identity unresolved","Neuronal substrates not identified"]},{"year":null,"claim":"It remains unresolved how the same O-glycosylation modification produces opposite signaling outcomes across tissues and how specific substrate glycosites mechanistically translate into the lipid, insulin, neurodevelopmental, and antiviral phenotypes.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Direct glycosite-to-phenotype causality largely uncharacterized","Reconciliation of catalytic vs. proposed RNA-binding/neuronal-marker roles missing","Substrate hierarchy driving each physiological output unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,7,8,25]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,11,22]}],"localization":[],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,8,18]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,11,16]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,5,14,15]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[12]}],"complexes":[],"partners":["APOC3","ANGPTL3","PLTP","EGFR","MET","AXL","IGF1R","ITGA5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q10471","full_name":"Polypeptide N-acetylgalactosaminyltransferase 2","aliases":["Polypeptide GalNAc transferase 2","GalNAc-T2","pp-GaNTase 2","Protein-UDP acetylgalactosaminyltransferase 2","UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 2"],"length_aa":571,"mass_kda":64.7,"function":"Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Has a broad spectrum of substrates for peptides such as EA2, Muc5AC, Muc1a, Muc1b. Probably involved in O-linked glycosylation of the immunoglobulin A1 (IgA1) hinge region. Involved in O-linked glycosylation of APOC-III, ANGPTL3 and PLTP. It participates in the regulation of HDL-C metabolism (PubMed:27508872, PubMed:32293671)","subcellular_location":"Golgi apparatus, Golgi stack membrane; Secreted","url":"https://www.uniprot.org/uniprotkb/Q10471/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GALNT2","classification":"Not Classified","n_dependent_lines":13,"n_total_lines":1208,"dependency_fraction":0.01076158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"GORASP2","stoichiometry":0.2},{"gene":"MKNK1","stoichiometry":0.2},{"gene":"RAB1A","stoichiometry":0.2},{"gene":"STX5","stoichiometry":0.2},{"gene":"TMED10","stoichiometry":0.2},{"gene":"TMED2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/GALNT2","total_profiled":1310},"omim":[{"mim_id":"618885","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIt; CDG2T","url":"https://www.omim.org/entry/618885"},{"mim_id":"615136","title":"UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 18; GALNT18","url":"https://www.omim.org/entry/615136"},{"mim_id":"615132","title":"UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 16; GALNT16","url":"https://www.omim.org/entry/615132"},{"mim_id":"615131","title":"UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 15; GALNT15","url":"https://www.omim.org/entry/615131"},{"mim_id":"610290","title":"UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 12; GALNT12","url":"https://www.omim.org/entry/610290"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Golgi apparatus","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GALNT2"},"hgnc":{"alias_symbol":["GalNAc-T2"],"prev_symbol":[]},"alphafold":{"accession":"Q10471","domains":[{"cath_id":"3.90.550.10","chopping":"77-359","consensus_level":"high","plddt":97.4486,"start":77,"end":359},{"cath_id":"2.80.10.50","chopping":"443-567","consensus_level":"high","plddt":95.583,"start":443,"end":567}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q10471","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q10471-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q10471-F1-predicted_aligned_error_v6.png","plddt_mean":89.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GALNT2","jax_strain_url":"https://www.jax.org/strain/search?query=GALNT2"},"sequence":{"accession":"Q10471","fasta_url":"https://rest.uniprot.org/uniprotkb/Q10471.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q10471/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q10471"}},"corpus_meta":[{"pmid":"27508872","id":"PMC_27508872","title":"Loss of Function of GALNT2 Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents.","date":"2016","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/27508872","citation_count":114,"is_preprint":false},{"pmid":"21990321","id":"PMC_21990321","title":"Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21990321","citation_count":99,"is_preprint":false},{"pmid":"22152306","id":"PMC_22152306","title":"Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man.","date":"2011","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22152306","citation_count":89,"is_preprint":false},{"pmid":"24582885","id":"PMC_24582885","title":"GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.","date":"2014","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24582885","citation_count":85,"is_preprint":false},{"pmid":"32293671","id":"PMC_32293671","title":"Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function.","date":"2020","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32293671","citation_count":64,"is_preprint":false},{"pmid":"25084356","id":"PMC_25084356","title":"A preliminary study of the relationship between promoter methylation of the ABCG1, GALNT2 and HMGCR genes and coronary heart disease.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25084356","citation_count":50,"is_preprint":false},{"pmid":"26637976","id":"PMC_26637976","title":"Multiple Hepatic Regulatory Variants at the GALNT2 GWAS Locus Associated with High-Density Lipoprotein Cholesterol.","date":"2015","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26637976","citation_count":49,"is_preprint":false},{"pmid":"31076460","id":"PMC_31076460","title":"Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis.","date":"2019","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31076460","citation_count":45,"is_preprint":false},{"pmid":"26848976","id":"PMC_26848976","title":"Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26848976","citation_count":40,"is_preprint":false},{"pmid":"36058918","id":"PMC_36058918","title":"The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer.","date":"2022","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/36058918","citation_count":35,"is_preprint":false},{"pmid":"23894607","id":"PMC_23894607","title":"GALNT2 expression is reduced in patients with Type 2 diabetes: possible role of hyperglycemia.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23894607","citation_count":32,"is_preprint":false},{"pmid":"33785338","id":"PMC_33785338","title":"GALNT2 promotes cell proliferation, migration, and invasion by activating the Notch/Hes1-PTEN-PI3K/Akt signaling pathway in lung adenocarcinoma.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33785338","citation_count":28,"is_preprint":false},{"pmid":"26744084","id":"PMC_26744084","title":"Association between the DOCK7, PCSK9 and GALNT2 Gene Polymorphisms and Serum Lipid levels.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26744084","citation_count":28,"is_preprint":false},{"pmid":"30323967","id":"PMC_30323967","title":"The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities.","date":"2018","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30323967","citation_count":28,"is_preprint":false},{"pmid":"23500900","id":"PMC_23500900","title":"Role of GALNT2 in the modulation of ENPP1 expression, and insulin signaling and action: GALNT2: a novel modulator of insulin signaling.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23500900","citation_count":27,"is_preprint":false},{"pmid":"21933382","id":"PMC_21933382","title":"Association of the GALNT2 gene polymorphisms and several environmental factors with serum lipid levels in the Mulao and Han populations.","date":"2011","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/21933382","citation_count":25,"is_preprint":false},{"pmid":"23117232","id":"PMC_23117232","title":"Expression of GALNT2 in human extravillous trophoblasts and its suppressive role in trophoblast invasion.","date":"2012","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/23117232","citation_count":24,"is_preprint":false},{"pmid":"36409270","id":"PMC_36409270","title":"GALNT2 promotes invasiveness of colorectal cancer cells partly through AXL.","date":"2022","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36409270","citation_count":21,"is_preprint":false},{"pmid":"32999434","id":"PMC_32999434","title":"GALNT2 regulates ANGPTL3 cleavage in cells and in vivo of mice.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32999434","citation_count":20,"is_preprint":false},{"pmid":"30096295","id":"PMC_30096295","title":"Paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice.","date":"2018","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30096295","citation_count":19,"is_preprint":false},{"pmid":"26493351","id":"PMC_26493351","title":"Association of the variants and haplotypes in the DOCK7, PCSK9 and GALNT2 genes and the risk of hyperlipidaemia.","date":"2015","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26493351","citation_count":19,"is_preprint":false},{"pmid":"31040393","id":"PMC_31040393","title":"GALNT2 as a novel modulator of adipogenesis and adipocyte insulin signaling.","date":"2019","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/31040393","citation_count":18,"is_preprint":false},{"pmid":"26817450","id":"PMC_26817450","title":"Looking beyond GWAS: allele-specific transcription factor binding drives the association of GALNT2 to HDL-C plasma levels.","date":"2016","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/26817450","citation_count":17,"is_preprint":false},{"pmid":"35055114","id":"PMC_35055114","title":"Role of GALNT2 on Insulin Sensitivity, Lipid Metabolism and Fat Homeostasis.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35055114","citation_count":16,"is_preprint":false},{"pmid":"37862385","id":"PMC_37862385","title":"Quantitative mapping of the in vivo O-GalNAc glycoproteome in mouse tissues identifies GalNAc-T2 O-glycosites in metabolic disorder.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37862385","citation_count":16,"is_preprint":false},{"pmid":"29601100","id":"PMC_29601100","title":"Structural Analysis of a GalNAc-T2 Mutant Reveals an Induced-Fit Catalytic Mechanism for GalNAc-Ts.","date":"2018","source":"Chemistry (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/29601100","citation_count":16,"is_preprint":false},{"pmid":"28153384","id":"PMC_28153384","title":"GALNT2 effect on HDL-cholesterol and triglycerides levels in humans: Evidence of pleiotropy?","date":"2016","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/28153384","citation_count":14,"is_preprint":false},{"pmid":"25573592","id":"PMC_25573592","title":"Functional variants of lipid level modifier MLXIPL, GCKR, GALNT2, CILP2, ANGPTL3 and TRIB1 genes in healthy Roma and Hungarian populations.","date":"2015","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/25573592","citation_count":14,"is_preprint":false},{"pmid":"33152927","id":"PMC_33152927","title":"Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O-glycosylating enzyme GALNT2.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/33152927","citation_count":12,"is_preprint":false},{"pmid":"30759204","id":"PMC_30759204","title":"IgA1 hinge-region clustered glycan fidelity is established early during semi-ordered glycosylation by GalNAc-T2.","date":"2019","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30759204","citation_count":12,"is_preprint":false},{"pmid":"35304331","id":"PMC_35304331","title":"A novel role for GalNAc-T2 dependent glycosylation in energy homeostasis.","date":"2022","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35304331","citation_count":11,"is_preprint":false},{"pmid":"26405973","id":"PMC_26405973","title":"Gene environment interaction of GALNT2 and APOE gene with hypertension in the Chinese Han Population.","date":"2015","source":"Bio-medical materials and engineering","url":"https://pubmed.ncbi.nlm.nih.gov/26405973","citation_count":11,"is_preprint":false},{"pmid":"34322281","id":"PMC_34322281","title":"Structural basis for peptide substrate specificities of glycosyltransferase GalNAc-T2.","date":"2021","source":"ACS catalysis","url":"https://pubmed.ncbi.nlm.nih.gov/34322281","citation_count":10,"is_preprint":false},{"pmid":"22033505","id":"PMC_22033505","title":"Production of N-acetylgalactosaminyl-transferase 2 (GalNAc-T2) fused with secretory signal Igκ in insect cells.","date":"2011","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/22033505","citation_count":10,"is_preprint":false},{"pmid":"37834292","id":"PMC_37834292","title":"Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37834292","citation_count":8,"is_preprint":false},{"pmid":"33171515","id":"PMC_33171515","title":"GALNT2 Gene Variant rs4846914 Is Associated with Insulin and Insulin Resistance Depending on BMI in PCOS Patients: a Case-Control Study.","date":"2020","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/33171515","citation_count":8,"is_preprint":false},{"pmid":"37597090","id":"PMC_37597090","title":"GALNT2, an O-glycosylating enzyme, is a critical regulator of radioresistance of non-small cell lung cancer: evidence from an integrated multi-omics analysis.","date":"2023","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/37597090","citation_count":7,"is_preprint":false},{"pmid":"34267728","id":"PMC_34267728","title":"Maternal GALNT2 Variations Affect Blood Pressure, Atherogenic Index, and Fetal Growth, Depending on BMI in Gestational Diabetes Mellitus.","date":"2021","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34267728","citation_count":7,"is_preprint":false},{"pmid":"37000153","id":"PMC_37000153","title":"GALNT2 sustains glioma stem cells by promoting CD44 expression.","date":"2023","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/37000153","citation_count":6,"is_preprint":false},{"pmid":"21532840","id":"PMC_21532840","title":"A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies.","date":"2010","source":"International journal of molecular epidemiology and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21532840","citation_count":5,"is_preprint":false},{"pmid":"39613794","id":"PMC_39613794","title":"GalNT2-mediated O-glycosylation affects pancreas development and function in mice.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39613794","citation_count":4,"is_preprint":false},{"pmid":"40095226","id":"PMC_40095226","title":"Exploring the combined roles of GALNT1 and GALNT2 in hepatocellular carcinoma malignancy and EGFR modulation.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40095226","citation_count":4,"is_preprint":false},{"pmid":"33658684","id":"PMC_33658684","title":"Morphological and molecular characterization of GALNT2-mediated adipogenesis.","date":"2021","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/33658684","citation_count":3,"is_preprint":false},{"pmid":"41092902","id":"PMC_41092902","title":"Galnt2 neurons in the ventromedial hypothalamus counterregulate hypoglycemia via a brain-liver neurocircuit.","date":"2025","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/41092902","citation_count":2,"is_preprint":false},{"pmid":"36861373","id":"PMC_36861373","title":"Leveraging Genetics to Address the Role of GALNT2 on Atherogenic Dyslipidemia.","date":"2023","source":"Advanced biology","url":"https://pubmed.ncbi.nlm.nih.gov/36861373","citation_count":2,"is_preprint":false},{"pmid":"38478152","id":"PMC_38478152","title":"GALNT2 targeted by miR-139-5p promotes proliferation of clear cell renal cell carcinoma via inhibition of LATS2 activation.","date":"2024","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38478152","citation_count":2,"is_preprint":false},{"pmid":"38999895","id":"PMC_38999895","title":"Gastroprotective Effect of Isoferulic Acid Derived from Foxtail Millet Bran against Ethanol-Induced Gastric Mucosal Injury by Enhancing GALNT2 Enzyme Activity.","date":"2024","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/38999895","citation_count":2,"is_preprint":false},{"pmid":"41387548","id":"PMC_41387548","title":"Interferon-stimulated gene GALNT2 restricts respiratory virus infections.","date":"2025","source":"Nature microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/41387548","citation_count":1,"is_preprint":false},{"pmid":"36874359","id":"PMC_36874359","title":"Role of a novel mouse mutant of the Galnt2  gene in otitis media.","date":"2023","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36874359","citation_count":1,"is_preprint":false},{"pmid":"38627282","id":"PMC_38627282","title":"GALNT2 expression is associated with glucose control and serum metabolites in patients with type 2 diabetes.","date":"2024","source":"Acta diabetologica","url":"https://pubmed.ncbi.nlm.nih.gov/38627282","citation_count":0,"is_preprint":false},{"pmid":"36374960","id":"PMC_36374960","title":"Effects of RNA Modification \"Writers\" of GALNT2 on the Tumor Microenvironment in Cervical Squamous Cell Carcinoma.","date":"2022","source":"Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36374960","citation_count":0,"is_preprint":false},{"pmid":"37885477","id":"PMC_37885477","title":"Corrigendum: Role of a novel mouse mutant of the Galnt2 gene in otitis media.","date":"2023","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37885477","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.09.30.615951","title":"Neuronal loss of  <i>Galnt2</i>  Impairs O-glycosylation and Leads to Neurobehavioral Deficits Mimicking GALNT2-CDG","date":"2024-10-02","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.30.615951","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.26.600229","title":"Midline Assembloids Reveal Regulators of Human Axon Guidance","date":"2024-06-26","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.26.600229","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":29713,"output_tokens":7906,"usd":0.103864,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17408,"output_tokens":4866,"usd":0.104345,"stage2_stop_reason":"end_turn"},"total_usd":0.208209,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"ppGalNAc-T2 (GALNT2) directly O-glycosylates apolipoprotein C-III (apoC-III); a loss-of-function mutation impairs this glycosylation, leading to attenuated apoC-III inhibition of lipoprotein lipase (LPL) and improved postprandial triglyceride clearance. An apoC-III-based peptide was validated as a substrate for ppGalNAc-T2, and neuraminidase removal of sialic acids from apoC-III glycans decreased its ability to inhibit LPL.\",\n      \"method\": \"In vitro glycosylation assay with apoC-III-based peptide substrate; neuraminidase treatment; plasma glycoproteomics in human carriers of GALNT2 loss-of-function mutation\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro substrate assay with mutagenesis-equivalent (loss-of-function mutant), peptide glycosylation assay, and functional neuraminidase experiment confirming mechanistic link to LPL inhibition; replicated in human subjects\",\n      \"pmids\": [\"22152306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GALNT2 deficiency reduces plasma PLTP (phospholipid transfer protein) activity and lowers HDL-C across mammals. O-glycoproteomics of a GALNT2-deficient human validated ANGPTL3 and ApoC-III as direct GalNAc-T2 substrates; additional rodent glycoproteomics identified PLTP as a substrate. Hepatic reconstitution of Galnt2 in mice rescued plasma PLTP activity.\",\n      \"method\": \"O-glycoproteomics in human GALNT2-deficient subject and rodents; hepatic Galnt2 reconstitution in mice; plasma PLTP activity assay\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vivo glycoproteomics, rescue by hepatic reconstitution, replicated across multiple mammalian species and orthogonal assays\",\n      \"pmids\": [\"27508872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GALNT2 modifies O-glycans on EGFR in hepatocellular carcinoma (HCC) cells, altering EGFR responses after EGF binding and suppressing EGF-induced cell growth, migration, and invasion. Inhibiting EGFR with erlotinib rescued the pro-malignant phenotypes caused by GALNT2 knockdown, establishing EGFR as a key downstream mediator.\",\n      \"method\": \"siRNA knockdown and overexpression of GALNT2 in HCC cells; in vitro growth/migration/invasion assays; in vivo xenograft; erlotinib epistasis experiment; Western blot for EGFR signaling\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (EGFR inhibitor rescue), loss- and gain-of-function, in vitro and in vivo, replicated in multiple cancer contexts\",\n      \"pmids\": [\"21990321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GALNT2 downregulation increases ENPP1 expression and impairs insulin receptor (IR), IRS-1, and Akt phosphorylation, as well as insulin-mediated suppression of PEPCK in human HepG2 liver cells. Conversely, GALNT2 overexpression reduces ENPP1 levels and enhances insulin signaling. GALNT2 was identified as a trans-acting factor binding the ENPP1 3′-UTR by RNA pull-down and mass spectrometry.\",\n      \"method\": \"RNA pull-down with mass spectrometry; RT-PCR; Western blot for ENPP1, IR, IRS-1, Akt phosphorylation; ELISA for IR autophosphorylation; siRNA knockdown and overexpression in HepG2 cells\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA pull-down/MS plus functional insulin signaling readouts in a single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23500900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GALNT2 modifies O-glycans on EGFR in oral squamous cell carcinoma (OSCC) cells, enhancing EGF-induced EGFR and AKT phosphorylation and promoting cell migration and invasion. VVA lectin pull-down confirmed increased Tn antigen on EGFR upon GALNT2 overexpression.\",\n      \"method\": \"Overexpression and siRNA knockdown of GALNT2 in SAS cells; Vicia villosa agglutinin (VVA) pull-down assay; transwell migration/invasion assay; Western blot\",\n      \"journal\": \"Oral oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — lectin pull-down and functional assays, single lab, consistent with parallel HCC findings\",\n      \"pmids\": [\"24582885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GALNT2 suppresses malignant phenotypes in gastric adenocarcinoma (GCA) by modifying O-glycosylation of MET (hepatocyte growth factor receptor), reducing its phosphorylation. GALNT2 knockdown decreased Tn antigen expression on MET and enhanced MET phosphorylation; MET inhibitor PHA665752 reversed the pro-malignant effects of GALNT2 knockdown.\",\n      \"method\": \"siRNA knockdown of GALNT2 in GCA cells; Tn antigen detection by Western blot; in vitro growth/migration/invasion; in vivo metastasis; MET inhibitor epistasis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with MET inhibitor, loss-of-function with in vivo validation, single lab\",\n      \"pmids\": [\"26848976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GALNT2 suppresses GCA malignancy through O-glycosylation of EGFR, reducing EGFR and Akt phosphorylation. GALNT2 knockdown decreased Tn antigen on EGFR; EGFR inhibitor gefitinib and Akt inhibitor MK2206 reversed pro-invasive effects of GALNT2 knockdown.\",\n      \"method\": \"siRNA knockdown in AGS/MKN28 cells; Western blot for pEGFR, pAkt, Tn antigen; migration/invasion assays; gefitinib/MK2206 epistasis\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis with EGFR/Akt inhibitors, Tn antigen detection, single lab\",\n      \"pmids\": [\"30323967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A GalNAc-T2 F104S mutant (not located at the active site) loses peptide substrate binding. Crystal structure of the mutant bound to UDP-GalNAc, combined with STD-NMR and MD simulations, revealed that the flexible loop is disordered in the mutant. 19F NMR demonstrated that wild-type GalNAc-T2 reaches the active state only in the presence of UDP-GalNAc, establishing a UDP-GalNAc-dependent induced-fit catalytic mechanism.\",\n      \"method\": \"Crystal structure of F104S mutant bound to UDP-GalNAc; saturation transfer difference (STD) NMR; 19F NMR spectroscopy; molecular dynamics simulations; active-site mutagenesis (F104S)\",\n      \"journal\": \"Chemistry (Weinheim an der Bergstrasse, Germany)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with NMR validation and MD simulations, multiple orthogonal methods establishing the induced-fit mechanism\",\n      \"pmids\": [\"29601100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GalNAc-T2 glycosylates IgA1 hinge-region in a semi-ordered process: the catalytic domain selects four initial sites based on amino-acid sequence recognition, and both the catalytic and lectin domains participate in subsequent site selections. The lectin domain enhances glycan density by increasing pathway exploration, linking site-specific glycan addition to overall clustered glycan density.\",\n      \"method\": \"In vitro glycosylation assay with IgA1 hinge-region peptide; LC-MS analysis of glycoforms; domain mutant analysis (catalytic vs. lectin domain)\",\n      \"journal\": \"Glycobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro assay with LC-MS, domain-specific functional dissection, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"30759204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GALNT2 facilitates glioma malignancy by O-glycosylating EGFR (detected by Tn antigen on EGFR via lectin pull-down), increasing EGFR phosphorylation and activating the PI3K/Akt/mTOR pathway, and regulating downstream effectors (p21, CDK4, cyclinD1, MMP2, MMP9).\",\n      \"method\": \"GALNT2 knockdown and overexpression in glioma cell lines; lectin pull-down; Western blot for pEGFR, PI3K/Akt/mTOR components; in vivo orthotopic xenograft with GALNT2 shRNA\",\n      \"journal\": \"Clinical science (London, England : 1979)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — lectin pull-down for substrate, functional in vitro and in vivo experiments, single lab\",\n      \"pmids\": [\"31076460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GALNT2 O-glycosylates β1-integrin (increasing Tn antigen on β1-integrin detected by VVA binding) in extravillous trophoblast (EVT) cells, enhancing cell-collagen IV adhesion but suppressing FAK phosphorylation, cell migration, and invasion.\",\n      \"method\": \"Overexpression of GALNT2 in HTR8/SVneo cells; VVA lectin binding assay for Tn antigen on β1-integrin; collagen IV adhesion assay; transwell migration/invasion; Western blot for phospho-FAK\",\n      \"journal\": \"Placenta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — lectin pull-down confirming substrate glycosylation, FAK signaling readout, single lab with multiple assays\",\n      \"pmids\": [\"23117232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GALNT2-mediated O-glycosylation near the ANGPTL3 cleavage site inhibits proprotein convertase (PC)-mediated cleavage of ANGPTL3. In primary hepatocytes and in vivo in mice, suppression of Galnt2 dramatically increases Angptl3 cleavage, while Galnt2 overexpression blocks cleavage; cleavage is also blocked by PC inhibition.\",\n      \"method\": \"Galnt2 overexpression and siRNA knockdown in primary hepatocytes and in vivo mouse liver; Western blot for ANGPTL3 cleavage products; PC inhibitor comparison\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro and in vivo experiments with both gain- and loss-of-function, PC inhibitor epistasis confirming mechanism, multiple orthogonal approaches\",\n      \"pmids\": [\"32999434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GALNT2 loss of function causes a congenital disorder of glycosylation (GALNT2-CDG) characterized by loss of O-glycosylation of ApoC-III (a non-redundant GALNT2 substrate), low HDL-C, and multisystem developmental abnormalities. Rodent models of GALNT2-CDG recapitulate neurodevelopmental phenotypes including cerebellar motor deficits, decreased sociability, and impaired sensory processing.\",\n      \"method\": \"Human patient biochemical and glycoproteomics analysis; mouse and rat GALNT2 knockout models; behavioral phenotyping\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — validated in human patients plus two rodent model systems with ApoC-III glycoproteomics and behavioral readouts\",\n      \"pmids\": [\"32293671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GALNT2 promotes adipogenesis and enhances insulin-induced IR, IRS1, and AKT activation in mouse 3T3-L1 preadipocytes, with the insulin-sensitizing effect abolished during late adipocyte maturation. GALNT2's effect is paralleled by coordinated changes in Enpp1 expression.\",\n      \"method\": \"Stable GALNT2 overexpression in 3T3-L1 cells; Oil Red-O staining; fluorimetric triglyceride assay; confocal microscopy of lipid droplets; Western blot for IR, IRS1, JNK, AKT phosphorylation; RT-PCR for adipogenesis genes\",\n      \"journal\": \"International journal of obesity (2005)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — multiple cellular readouts with overexpression, single lab\",\n      \"pmids\": [\"31040393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GALNT2 modifies O-glycans on ITGA5 (integrin alpha 5) in non-small cell lung cancer cells, affecting activation of the PI3K/Akt and MAPK/ERK pathways. miR-30d was identified as a negative regulator of GALNT2 by high-throughput sequencing.\",\n      \"method\": \"Lectin pull-down for O-glycosylation of ITGA5; gain- and loss-of-function experiments; Western blot for PI3K/Akt, MAPK/ERK; in vivo tumor formation; miRNA high-throughput sequencing\",\n      \"journal\": \"Cellular & molecular biology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — lectin pull-down confirming ITGA5 as substrate, signaling pathway readouts, single lab\",\n      \"pmids\": [\"36058918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GALNT2 modifies O-glycans on AXL receptor tyrosine kinase in colorectal cancer cells and regulates AXL protein levels via the proteasome-dependent pathway; GALNT2-promoted invasiveness was significantly reversed by AXL siRNA knockdown.\",\n      \"method\": \"GALNT2 overexpression and CRISPR/Cas9 knockout; siRNA knockdown; lectin pull-down for O-glycans on AXL; proteasome inhibitor experiments; migration/invasion and peritoneal metastasis assays\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO plus lectin pull-down for substrate identification, epistasis with AXL siRNA, single lab\",\n      \"pmids\": [\"36409270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The insulin receptor is a novel O-glycosylation substrate of GalNAc-T2. Galnt2-knockout mice display decreased adiposity, altered insulin signaling, and a shift in energy substrate utilization in the inactive phase.\",\n      \"method\": \"Galnt2-/- mouse model; glycoproteomics identifying insulin receptor as substrate; metabolic phenotyping including indirect calorimetry; GWAS correlation in UK Biobank\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo glycoproteomics identifying insulin receptor as substrate, KO mouse metabolic phenotyping, single lab\",\n      \"pmids\": [\"35304331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Computational flexible docking of peptide substrates into GalNAc-T2 identified enzyme residues R362, K363, Q364, H365, and W331 as regulators of pocket size and peptide binding at the -1 position, and K281 and K363 as gating residues at the +1 position, explaining the finely tuned peptide substrate specificity of GalNAc-T2.\",\n      \"method\": \"Rosetta Monte Carlo-minimization flexible docking of 361 peptides with experimental glycosylation efficiency data; computational scanning of enzyme-peptide interactions\",\n      \"journal\": \"ACS catalysis\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Moderate — computational prediction validated against experimental dataset but no direct mutagenesis of identified residues performed in this study\",\n      \"pmids\": [\"34322281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In vivo O-glycoproteomics in Galnt2-null mice identified a network of glycoproteins lacking GalNAc-T2-specific O-glycans across nine mouse tissues, establishing tissue-specific regulation of O-glycosites. Known functions of these glycoproteins are consistent with the complex metabolic phenotypes of Galnt2-null animals.\",\n      \"method\": \"Quantitative glycoproteomics and proteomics across nine mouse tissues using HCD-triggered ETD/HCD MS; Galnt2-null mouse model comparison\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — comprehensive in vivo MS glycoproteomics in KO vs. WT across multiple tissues with rigorous quantitative workflow\",\n      \"pmids\": [\"37862385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GALNT2 modifies O-glycans on IGF1R in non-small cell lung cancer cells (detected by lectin pull-down), and IGF1R affects expression of apoptosis-related genes. GALNT2 knockdown-mediated radiosensitization was enhanced by IGF1R inhibition. miR-30a-5p was validated as an upstream negative regulator of GALNT2 by luciferase reporter assay.\",\n      \"method\": \"Lectin pull-down for O-glycans on IGF1R; GALNT2 knockdown; in vitro and in vivo radiosensitivity assays; IGF1R inhibitor epistasis; miRNA array; dual luciferase reporter assay\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — lectin pull-down for substrate, epistasis with IGF1R inhibitor, luciferase validation of upstream regulator, single lab\",\n      \"pmids\": [\"37597090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GALNT2 overexpression specifically in the pancreas (conditional transgenic mouse) causes loss of acinar mass and pancreatic steatosis (heterozygous) or complete pancreatic loss with lethal phenotype (homozygous). Adipocytes in the pancreas were shown to originate via transdifferentiation from pancreatic cells (reporter gene mouse). Additional O-glycosylation sites introduced by GalNT2 overexpression were identified by PNA lectin enrichment and mass spectrometric proteome analysis.\",\n      \"method\": \"Conditional transgenic mouse with pancreas-specific GalNT2 overexpression; reporter gene mouse for lineage tracing; PNA lectin enrichment and mass spectrometry\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo conditional overexpression with histological and proteomic validation, single lab\",\n      \"pmids\": [\"39613794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GALNT2 knockdown in renal cell carcinoma cells increased p-LATS2/LATS2 expression and subsequent YAP phosphorylation/degradation, suppressing cell proliferation. This was rescued by LATS2 knockdown, placing GALNT2 upstream of LATS2 in this pathway. miR-139-5p was validated as a direct negative regulator of GALNT2 via dual luciferase reporter assay targeting the GALNT2 3′-UTR.\",\n      \"method\": \"shRNA knockdown of GALNT2; LATS2 epistasis (double knockdown rescue); Western blot for p-LATS2, LATS2, p-YAP, YAP; dual luciferase reporter assay for miR-139-5p/GALNT2 3′-UTR interaction\",\n      \"journal\": \"Discover oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — epistasis rescue experiment plus luciferase validation of upstream regulator, single lab\",\n      \"pmids\": [\"38478152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GALNT2 is an interferon-stimulated gene (ISG) that restricts replication of multiple coronaviruses and influenza A viruses in vitro and in vivo. Mechanistically, GALNT2-dependent O-linked glycosylation of the SARS-CoV-2 spike protein at serine 810/813 regulates viral glycoprotein proteolytic processing and impairs virus-cell fusion. Human GALNT2 loss-of-function variants are associated with elevated risk of COVID-19 hospitalization.\",\n      \"method\": \"Transcriptomic profiling of IFNAR-/- vs. wild-type mouse lungs; single-cell RNA-seq of COVID-19 patient samples; in vitro viral replication assays; in vivo infection models; site-directed mutagenesis of spike S810/813; mechanistic fusion assay\",\n      \"journal\": \"Nature microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro and in vivo antiviral experiments, mutagenesis of glycosylation sites on viral substrate, multiple virus types tested, human genetic validation\",\n      \"pmids\": [\"41387548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Galnt2-expressing neurons in the ventromedial hypothalamus (VMH) form a VMH→PVH→LPGi→liver neurocircuit that detects neuroglycopenia and drives hepatic glucose production via intrahepatic sympathetic activation. Galnt2 functions as both a genetic marker and molecular brake of VMH glucose-inhibited neurons, modulating the glycemic threshold for hypoglycemia perception.\",\n      \"method\": \"Viral tracing; single-nucleus RNA sequencing; behavioral and metabolic phenotyping; optogenetic/chemogenetic circuit dissection\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — circuit tracing and snRNA-seq with functional circuit manipulation, single study; Galnt2 used as a neuronal marker/target rather than enzymatic substrate identified\",\n      \"pmids\": [\"41092902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Neuronal-specific conditional knockout of Galnt2 in mice causes behavioral deficits (locomotion, motor coordination, sociability, learning, memory) and spontaneous seizures, recapitulating GALNT2-CDG neurology. Glycoproteomics of cortical synaptosomes identified a non-redundant, isoform-specific Galnt2 contribution to the synaptosomal O-glycoproteome, identifying disrupted O-glycosites on candidate neuronal glycoproteins.\",\n      \"method\": \"Pan-neuronal conditional Galnt2 knockout mouse; behavioral battery (locomotion, rotarod, social interaction, Morris water maze, EEG for seizures); cortical synaptosomal glycoproteomics\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with glycoproteomics and behavioral phenotyping; preprint, not peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2024.09.30.615951\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Recombinant soluble GalNAc-T2 produced in insect (Sf9) cells was enzymatically active, catalyzing GalNAc transfer to synthetic IgA1 hinge-region peptide using UDP-GalNAc as donor. This confirmed the enzyme's activity toward IgA1 hinge-region peptide substrates.\",\n      \"method\": \"Baculovirus expression and purification of recombinant GalNAc-T2; in vitro enzymatic activity assay quantifying GalNAc attachment to synthetic IgA1 HR peptide; mass spectrometric confirmation of protein identity\",\n      \"journal\": \"Protein expression and purification\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro enzymatic reconstitution demonstrating activity toward IgA1 HR substrate, single study with single method\",\n      \"pmids\": [\"22033505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GALNT2 promotes CD44 expression to sustain glioblastoma stem cells (GSCs), and STAT3 directly activates GALNT2 transcription by binding to the GALNT2 promoter. A GALNT2 inhibitor suppressed GSC self-maintenance in vitro and in vivo.\",\n      \"method\": \"GALNT2 knockdown in GSCs; CD44 expression analysis; ChIP assay for STAT3 binding to GALNT2 promoter; pharmacological GALNT2 inhibitor; in vivo xenograft\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP assay for upstream transcriptional regulation, loss-of-function with downstream substrate (CD44) analysis, single lab\",\n      \"pmids\": [\"37000153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GALNT2 was identified as a regulator of human commissural axon guidance by floor plate; CRISPR knockout of GALNT2 in human floor plate organoids impaired floor plate-mediated guidance of commissural axons in midline assembloids, implicating O-linked glycosylation in human-specific axon guidance.\",\n      \"method\": \"CRISPR knockout screen in human floor plate organoids (hFpO) assembled with spinal cord organoids (hSpO); secretome profiling; axon guidance assay in midline assembloids\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single arrayed CRISPR screen phenotype in an organoid model, preprint, mechanistic substrate not identified\",\n      \"pmids\": [\"bio_10.1101_2024.06.26.600229\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Isoferulic acid (IFA) directly interacts with GALNT2 protein (shown by Co-IP, molecular docking, and fluorescence spectroscopy) and inhibits alcohol-induced downregulation of GALNT2 activity in gastric epithelial cells, thereby promoting mucin synthesis.\",\n      \"method\": \"Co-immunoprecipitation; molecular docking; fluorescence spectroscopy; GALNT2 activity assay; in vivo rat gastric injury model; H&E staining; gastric hexosamine content\",\n      \"journal\": \"Nutrients\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — Co-IP and docking for interaction, functional assay, but mechanism is indirect and single lab with limited rigor\",\n      \"pmids\": [\"38999895\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GALNT2 encodes a Golgi-localized polypeptide N-acetylgalactosaminyltransferase (GalNAc-T2) that catalyzes the first committed step of mucin-type O-glycosylation via a UDP-GalNAc-dependent induced-fit mechanism; it O-glycosylates a broad array of protein substrates—including EGFR, MET, AXL, IGF1R, ITGA5, β1-integrin, the insulin receptor, ApoC-III, ANGPTL3, and PLTP—thereby regulating receptor tyrosine kinase signaling, lipoprotein metabolism (HDL-C and triglycerides through ANGPTL3 cleavage and LPL activity), insulin signaling via ENPP1 suppression, adipogenesis, antiviral defense through viral glycoprotein processing, and neuronal function, with loss-of-function causing a multi-system congenital disorder of glycosylation (GALNT2-CDG).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GALNT2 encodes a Golgi polypeptide N-acetylgalactosaminyltransferase (GalNAc-T2) that initiates mucin-type O-glycosylation by transferring GalNAc from UDP-GalNAc onto serine/threonine residues of secreted and membrane substrates [#0, #25]. Catalysis proceeds through a UDP-GalNAc-dependent induced-fit mechanism in which donor binding orders a flexible loop and drives the enzyme into its active state; a non-active-site F104S mutation abolishes peptide substrate binding by leaving this loop disordered [#7]. The catalytic domain selects initial glycosylation sites by sequence recognition while the lectin domain expands site exploration to increase clustered glycan density, as shown for the IgA1 hinge region [#8]. In hepatic and metabolic physiology, GalNAc-T2 O-glycosylates ApoC-III, ANGPTL3 and PLTP: glycosylation modulates ApoC-III-mediated inhibition of lipoprotein lipase, blocks proprotein-convertase cleavage of ANGPTL3, and sustains plasma PLTP activity, thereby controlling triglyceride clearance and HDL-C [#0, #1, #11]. GalNAc-T2 also glycosylates the insulin receptor and influences insulin signaling, in part through coordinated suppression of ENPP1, and promotes adipogenesis [#3, #16, #13]. Across multiple cancers it O-glycosylates receptor tyrosine kinases and adhesion receptors—EGFR, MET, AXL, IGF1R, ITGA5 and \\u03b21-integrin—tuning downstream PI3K/Akt, MAPK/ERK and FAK signaling with context-dependent suppressive or promoting effects on growth, migration and invasion [#2, #5, #14, #15, #10]. As an interferon-stimulated gene, GALNT2 O-glycosylates the SARS-CoV-2 spike at S810/813 to restrict viral glycoprotein processing and cell fusion, conferring antiviral activity [#22]. Loss of function causes a multisystem congenital disorder of glycosylation (GALNT2-CDG) with loss of ApoC-III O-glycosylation, low HDL-C, and neurodevelopmental phenotypes recapitulated in rodent models [#12].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"Established that GalNAc-T2 directly O-glycosylates a physiological substrate (ApoC-III) and that this modification is functionally consequential for lipid metabolism, linking the enzyme to triglyceride handling.\",\n      \"evidence\": \"In vitro peptide glycosylation, neuraminidase treatment, and plasma glycoproteomics in human loss-of-function carriers; recombinant enzyme activity on IgA1 hinge peptide\",\n      \"pmids\": [\"22152306\", \"22033505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which other plasma glycoproteins drive the metabolic phenotype\", \"Quantitative contribution of ApoC-III glycosylation to systemic triglyceride levels not isolated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed GalNAc-T2 glycosylation is not confined to secreted proteins but also modifies a membrane receptor (EGFR), establishing a route by which O-glycosylation tunes receptor tyrosine kinase signaling and tumor behavior.\",\n      \"evidence\": \"siRNA/overexpression in HCC cells, xenograft, and erlotinib epistasis with EGFR signaling readouts\",\n      \"pmids\": [\"21990321\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific EGFR O-glycosites not mapped\", \"Direct vs. indirect modification of EGFR not distinguished in this study\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended the receptor-substrate model to adhesion machinery by showing \\u03b21-integrin O-glycosylation alters cell-matrix adhesion and FAK signaling, indicating GalNAc-T2 controls cell migration through integrin glycosylation.\",\n      \"evidence\": \"GALNT2 overexpression in trophoblast cells with VVA lectin pull-down, adhesion and migration assays, phospho-FAK Western blot\",\n      \"pmids\": [\"23117232\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Lectin detection does not pinpoint the modified \\u03b21-integrin residues\", \"Single overexpression system\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Uncovered a glycosylation-independent branch in which GalNAc-T2 acts as a trans-acting factor on the ENPP1 3'-UTR to regulate insulin receptor signaling, broadening its role beyond enzymatic O-glycosylation.\",\n      \"evidence\": \"RNA pull-down/MS, knockdown/overexpression in HepG2 cells, insulin signaling and PEPCK readouts\",\n      \"pmids\": [\"23500900\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of ENPP1 3'-UTR binding by a Golgi glycosyltransferase not reconciled with its catalytic function\", \"Single-lab RNA pull-down without reciprocal validation\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Confirmed ANGPTL3 and PLTP as direct in vivo substrates and demonstrated rescue by hepatic reconstitution, cementing GalNAc-T2's causal role in HDL-C and lipid transfer physiology across mammals.\",\n      \"evidence\": \"O-glycoproteomics in human-deficient subject and rodents, hepatic Galnt2 reconstitution in mice, PLTP activity assay\",\n      \"pmids\": [\"27508872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative metabolic weight of PLTP vs. ANGPTL3 vs. ApoC-III not partitioned\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the catalytic logic of the enzyme by showing donor (UDP-GalNAc) binding orders a flexible loop to reach the active state, explaining how substrate recognition is gated by an induced-fit mechanism.\",\n      \"evidence\": \"Crystal structure of F104S mutant with UDP-GalNAc, STD-NMR, 19F NMR, MD simulations, active-site mutagenesis\",\n      \"pmids\": [\"29601100\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address how the lectin domain integrates with the catalytic cycle\", \"Single-substrate structural context\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Resolved how site-specific and clustered O-glycan density arise, attributing initial site selection to the catalytic domain and density amplification to lectin-domain-driven pathway exploration.\",\n      \"evidence\": \"In vitro IgA1 hinge glycosylation with LC-MS glycoform analysis and catalytic vs. lectin domain mutants\",\n      \"pmids\": [\"30759204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same domain division governs membrane-receptor substrates is untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed receptor-substrate effects are context-dependent, with EGFR/MET glycosylation promoting malignancy in some tumors and suppressing it in others, indicating tissue-specific signaling outcomes of the same modification.\",\n      \"evidence\": \"Lectin pull-down and inhibitor epistasis across glioma, gastric, oral cancer models with PI3K/Akt/mTOR and FAK readouts; insulin-sensitizing adipogenesis in 3T3-L1\",\n      \"pmids\": [\"31076460\", \"24582885\", \"26848976\", \"30323967\", \"31040393\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis for opposite directionality across tissues unexplained\", \"Glycosites on each receptor not mapped\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Provided in vivo mechanism for the lipid phenotype by showing O-glycosylation near the ANGPTL3 cleavage site blocks proprotein-convertase processing, directly coupling GalNAc-T2 to ANGPTL3 activation.\",\n      \"evidence\": \"Galnt2 gain/loss in primary hepatocytes and mouse liver, ANGPTL3 cleavage Western blots, PC inhibitor epistasis\",\n      \"pmids\": [\"32999434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of glycan occupancy needed to block cleavage not quantified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established GALNT2 loss as the cause of a defined human congenital disorder of glycosylation with multisystem and neurodevelopmental phenotypes, validated in rodent models.\",\n      \"evidence\": \"Human patient biochemistry/glycoproteomics, mouse and rat knockouts with behavioral phenotyping\",\n      \"pmids\": [\"32293671\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which substrate losses drive the neurological phenotype not pinned down\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Expanded the substrate repertoire to additional receptors (AXL, ITGA5, insulin receptor, IGF1R) and connected glycosylation to receptor stability, downstream pathway activation, and metabolic energy utilization.\",\n      \"evidence\": \"Lectin pull-down, CRISPR KO, proteasome inhibition, glycoproteomics in Galnt2-/- mice, metabolic phenotyping, inhibitor epistasis\",\n      \"pmids\": [\"36409270\", \"36058918\", \"35304331\", \"37597090\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct glycosite assignments on these receptors largely absent\", \"Single-lab findings per receptor\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Generated a comprehensive in vivo, tissue-specific map of GalNAc-T2-dependent O-glycosites, providing the substrate network underlying the enzyme's pleiotropic phenotypes.\",\n      \"evidence\": \"Quantitative glycoproteomics across nine tissues in Galnt2-null vs. WT mice; STAT3 ChIP for transcriptional control of GALNT2 in glioblastoma stem cells\",\n      \"pmids\": [\"37862385\", \"37000153\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of most individual glycosites untested\", \"Tissue-specific regulators of GALNT2 expression incompletely defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined an antiviral function for GALNT2 as an interferon-stimulated gene that glycosylates viral spike protein to impair proteolytic priming and fusion, with human genetic support linking loss of function to COVID-19 severity.\",\n      \"evidence\": \"IFNAR-/- transcriptomics, scRNA-seq of patients, in vitro/in vivo infection, spike S810/813 mutagenesis, fusion assays, human variant association\",\n      \"pmids\": [\"41387548\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Breadth of viral glycoprotein substrates beyond coronaviruses/influenza not fully delineated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Implicated Galnt2 in central glucose sensing, marking and braking VMH glucose-inhibited neurons within a hypothalamus-to-liver circuit controlling hepatic glucose production.\",\n      \"evidence\": \"Viral tracing, snRNA-seq, optogenetic/chemogenetic circuit dissection, metabolic phenotyping\",\n      \"pmids\": [\"41092902\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the neuronal role depends on enzymatic O-glycosylation or marker identity unresolved\", \"Neuronal substrates not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the same O-glycosylation modification produces opposite signaling outcomes across tissues and how specific substrate glycosites mechanistically translate into the lipid, insulin, neurodevelopmental, and antiviral phenotypes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct glycosite-to-phenotype causality largely uncharacterized\", \"Reconciliation of catalytic vs. proposed RNA-binding/neuronal-marker roles missing\", \"Substrate hierarchy driving each physiological output unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 7, 8, 25]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 11, 22]},\n      {\"term_id\": \"GO:0016757\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 8, 18]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 11, 16]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 5, 14, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"APOC3\", \"ANGPTL3\", \"PLTP\", \"EGFR\", \"MET\", \"AXL\", \"IGF1R\", \"ITGA5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}